Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs
President Donald Trump signed an executive order Saturday that he said "directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs." "These treatments are currently in the advanced stages of clinical trials to ensure that they're both safe and effective for the American patients,